COLUMBUS
COLUMBUS tested encorafenib-binimetinib, the third BRAF/MEK doublet, which has the longest median survival of the class and less fever than dabrafenib-trametinib.
Median PFS 14.9 months versus 7.3 for vemurafenib; median OS 33.6 months (7-year update: OS 27.7%). Approved June 2018. Distinguished by lower pyrexia and photosensitivity and by a longer dissociation half-life of encorafenib on BRAF.
- Median 14.9 vs 7.3 months with Encorafenib + binimetinib compared with Vemurafenib; about 7.6 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 46 percent lower chance of the event at any given time (hazard ratio 0.54).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Advanced BRAF V600 melanoma: encorafenib + binimetinib vs vemurafenib vs encorafenib. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (BRAF); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
577 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Encorafenib + binimetinib | — | 14.9 months | 0.54 | — | link |
| Vemurafenib | — | 7.3 months |
Pages like this
not linked directly; found by shared links- PairingBRAF inhibitor + MEK inhibitor
Shares Encorafenib, BRAF, RAS / RAF / MEK / ERK (MAPK), Melanoma.
- ProductCobimetinib
Shares Vemurafenib, BRAF, RAS / RAF / MEK / ERK (MAPK), Melanoma.
- PersonKeith T. Flaherty
Shares Vemurafenib, BRAF, Melanoma.
- TrialCOMBI-AD
Shares BRAF, RAS / RAF / MEK / ERK (MAPK), Melanoma.
- PersonGrant McArthur
Shares Vemurafenib, BRAF, Melanoma.
- TermBRAF V600E mutation
Shares Vemurafenib, BRAF, Melanoma.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Encorafenib, BRAF, Melanoma.
- TrialBREAKWATER
Shares Encorafenib, BRAF, RAS / RAF / MEK / ERK (MAPK).